+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Systemic Autoinflammatory Diseases Drug Market - Global Forecast 2026-2032- Product Image
Systemic Autoinflammatory Diseases Drug Market - Global Forecast 2026-2032- Product Image
New

Systemic Autoinflammatory Diseases Drug Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 183 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6080476
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The systemic autoinflammatory diseases drug market is undergoing profound transformation, with innovation, evidence expectations, and supply dynamics reshaping competition. Senior decision-makers seeking to navigate this environment require a clear understanding of segmentation, tariff impacts, and evolving adoption drivers.

Market Snapshot: Systemic Autoinflammatory Diseases Drug Market

The systemic autoinflammatory diseases drug market expanded from USD 1.04 billion in 2025 to USD 1.12 billion in 2026 and is set to grow at a CAGR of 8.24%, reaching USD 1.82 billion by 2032. This growth reflects not only advances in immunology and precision therapeutics but also an evolving operational and regulatory landscape as the sector shifts from singular cytokine blockade to more differentiated approaches.

Scope & Segmentation

This report provides comprehensive coverage and actionable insights across key market drivers, innovation trends, and segmentation, empowering leaders to advance portfolio strategy and operational resilience.

  • Mechanism Types: Biologics focused on interleukin and cytokine pathways, small molecules with broader pathway activity, therapies targeting upstream inflammasome components, and conventional corticosteroids or immunosuppressants as adjuncts or bridges.
  • Indication Scope: Monogenic periodic fever syndromes such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, hyper-IgD syndrome, and polygenic conditions including systemic juvenile idiopathic arthritis and adult-onset Still’s disease.
  • Route of Administration: Subcutaneous, intravenous, and oral options, each with practical implications on dosing, adherence, and site-of-care economics.
  • Distribution Channels: Hospital pharmacies for acute management, retail and specialty pharmacies for maintenance, and specialty distribution networks for complex cold-chain logistics and patient support.
  • Patient Segments: Pediatric populations requiring tailored dosing and monitoring, and adults with longer-term comorbidity risk and work productivity considerations.
  • Regions: Americas, Europe, Middle East, Africa, and Asia-Pacific, spanning diverse healthcare infrastructure, diagnostic capacities, and reimbursement frameworks.

Key Takeaways: Strategic Insights for Decision-Makers

  • Therapeutic development is advancing toward precision, targeting upstream disease mechanisms to improve durability and differentiate through efficacy, safety, and convenience.
  • Regulatory and payer expectations are increasing, requiring sustained clinical outcome data such as function, fatigue, growth in children, and steroid-sparing effects.
  • Operational resilience in supply chain and manufacturing is critical, with biopharmaceutical companies adopting dual sourcing, scalable processes, and cold-chain logistics as competitive differentiators.
  • Segmentation is shaping competition, with mechanism of action, indication heterogeneity, administration routes, and channel dynamics influencing real-world uptake and physician preference.
  • Pediatric needs and adult priorities differ significantly, making tailored product development and evidence generation essential to expand market share.
  • Regional adoption varies due to diagnostic infrastructure, health technology assessment processes, genetic testing availability, and distribution maturity.

Tariff Impact: Navigating Trade Complexity in 2025

With United States tariff policy shifts in 2025, operational costs across the entire value chain have become less predictable. Biologics, specialty packaging, diagnostic kits, and laboratory consumables are especially affected. Companies are mitigating risk by qualifying multiple suppliers, seeking regional alternatives, and investing in inventory management and resilient cold-chain logistics. These responses introduce operational trade-offs, requiring rigorous change management and validation to uphold quality, particularly as rapid supplier changes can compress launch timelines and impact manufacturing consistency. Commercially, this landscape pushes stakeholders to renegotiate contracts, adapt pricing, and emphasize uninterrupted supply to preserve trust with prescribers and payers.

Methodology & Data Sources

This analysis synthesizes peer-reviewed clinical research, clinical trial registries, regulatory filings, and public corporate data. Primary insights arise from stakeholder interviews with specialists in rheumatology, pharmacy benefit managers, distribution experts, and executives in medical affairs and market access. Rigorous triangulation ensures all findings are validated, consistent, and actionable for strategic planning.

Why This Report Matters

  • Facilitates strategic decision-making by connecting market drivers, supply risks, and innovation direction with real-world commercial outcomes.
  • Empowers organizations to anticipate regulatory and operational requirements, enhance clinical evidence strategy, and optimize access models nationwide and globally.
  • Supports portfolio positioning and risk mitigation with insights tailored for executive and scientific leaders seeking durable competitive advantage in immunology.

Conclusion

Integrating biomarker-led innovation, evidence generation, and supply chain resilience will set new standards for success in systemic autoinflammatory diseases drug markets. Senior stakeholders benefit from a holistic perspective to achieve clinical, operational, and commercial excellence as this landscape evolves.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Systemic Autoinflammatory Diseases Drug Market, by Drug Class
8.1. Il-1 Inhibitors
8.1.1. Anakinra
8.1.2. Canakinumab
8.1.3. Rilonacept
8.2. Interleukin-6 Receptor Blockade
8.2.1. Sarilumab
8.2.2. Tocilizumab
8.3. Jak Inhibitors
8.3.1. Baricitinib
8.3.2. Tofacitinib
8.3.3. Upadacitinib
8.4. Tnf Inhibitors
8.4.1. Adalimumab
8.4.2. Etanercept
8.4.3. Infliximab
9. Systemic Autoinflammatory Diseases Drug Market, by Mechanism Of Action
9.1. Interleukin-1 Blockade
9.2. Interleukin-6 Receptor Blockade
9.3. Janus Kinase Inhibition
9.4. Tumor Necrosis Factor Alpha Inhibition
10. Systemic Autoinflammatory Diseases Drug Market, by Route Of Administration
10.1. Intravenous Infusion
10.2. Oral Administration
10.3. Subcutaneous Injection
11. Systemic Autoinflammatory Diseases Drug Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
12. Systemic Autoinflammatory Diseases Drug Market, by End User
12.1. Clinics
12.2. Home Care
12.3. Hospitals
12.4. Specialty Centers
13. Systemic Autoinflammatory Diseases Drug Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Systemic Autoinflammatory Diseases Drug Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Systemic Autoinflammatory Diseases Drug Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Systemic Autoinflammatory Diseases Drug Market
17. China Systemic Autoinflammatory Diseases Drug Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Amgen Inc.
18.7. AstraZeneca PLC
18.8. Biogen Inc.
18.9. Bristol-Myers Squibb Company
18.10. CSL Behring LLC
18.11. Eli Lilly and Company
18.12. GlaxoSmithKline plc
18.13. Grifols SA
18.14. Horizon Therapeutics plc
18.15. Ipsen SA
18.16. Johnson & Johnson (Janssen Biotech)
18.17. Merck & Co. Inc.
18.18. Novartis AG
18.19. Novimmune SA
18.20. Pfizer Inc.
18.21. Regeneron Pharmaceuticals, Inc.
18.22. Roche Holding AG
18.23. Sanofi S.A.
18.24. Swedish Orphan Biovitrum AB
18.25. Takeda Pharmaceutical Company Limited
18.26. UCB SA
List of Figures
FIGURE 1. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ANAKINRA, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ANAKINRA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ANAKINRA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CANAKINUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CANAKINUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CANAKINUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RILONACEPT, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RILONACEPT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RILONACEPT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SARILUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SARILUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SARILUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOCILIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOCILIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOCILIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BARICITINIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BARICITINIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BARICITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOFACITINIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOFACITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY UPADACITINIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY UPADACITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ETANERCEPT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ETANERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-1 BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-1 BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-1 BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JANUS KINASE INHIBITION, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JANUS KINASE INHIBITION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JANUS KINASE INHIBITION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITION, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 141. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 142. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 143. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 144. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 145. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 146. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 147. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 161. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 162. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 163. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 164. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 165. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 166. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 180. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 182. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 183. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 184. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 185. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 186. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 187. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 189. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 190. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 191. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 192. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 193. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 194. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 195. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 196. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 197. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 198. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 199. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 212. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 213. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 214. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 215. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 216. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 217. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 220. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 221. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 222. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 223. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 224. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 225. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 226. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 227. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 228. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 231. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 232. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 233. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 234. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 235. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 236. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 237. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 238. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 240. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 241. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 242. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 243. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 246. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 251. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 252. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 253. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 254. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
TABLE 255. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 256. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 257. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 258. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 259. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 260. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Systemic Autoinflammatory Diseases Drug market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CSL Behring LLC
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Grifols SA
  • Horizon Therapeutics plc
  • Ipsen SA
  • Johnson & Johnson (Janssen Biotech)
  • Merck & Co. Inc.
  • Novartis AG
  • Novimmune SA
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • UCB SA

Table Information

Report AttributeDetails
No. of Pages183
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.12 Billion
Forecasted Market Value ( USD ) by 2032 $ 1.82 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Uveitis Treatment Market - Global Forecast 2026-2032 - Product Image

Uveitis Treatment Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Clinical Immunology. Principles and Practice. Edition No. 6 - Product Image

Clinical Immunology. Principles and Practice. Edition No. 6

  • Book
The Microbiome in Cancer and Autoimmunity - Part B. International Review of Cell and Molecular Biology Volume 395 - Product Image

The Microbiome in Cancer and Autoimmunity - Part B. International Review of Cell and Molecular Biology Volume 395

  • Book
  • Global
The Rose and Mackay Textbook of Autoimmune Diseases. Edition No. 7 - Product Image

The Rose and Mackay Textbook of Autoimmune Diseases. Edition No. 7

  • Book
Rheumatology Secrets. Edition No. 4 - Product Image

Rheumatology Secrets. Edition No. 4

  • Book
Copyright © 2002-2026 Research and Markets. All Rights Reserved.